Randomised clinical trial: High-dose acid suppression for chronic cough - A double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 2, 2011, Pages 225-234

  Shaheen, N J ^a   Crockett, S D ^a   Bright, S D ^a   Madanick, R D ^a   Buckmire, R ^a   Couch, M ^a   Dellon, E S ^a   Galanko, J A ^a   Sharpless, G ^a   Morgan, D R ^a   Spacek, M B ^a   Heidt Davis, P ^a   Henke, D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; METHACHOLINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGH SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; COUGHING; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; ESOPHAGUS PH; FEMALE; FISMAN COUGH FREQUENCY SCORE; FISMAN COUGH SEVERITY SCORE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LARYNGOSCOPY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; COUGH; DOUBLE-BLIND METHOD; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650301500     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04511.x     Document Type: Article

References (45)

1. Wynder EL, Lemon FR, Mantel N,. Epidemiology of persistent cough. Am Rev Respir Dis 1965; 91: 679-700.
2. Woodwell DA, Cherry DK,. National Ambulatory Medical Care Survey: 2002 summary. Adv Dat 2004; 26: 1-44.
3. Di Pede C, Viegi G, Quackenboss JJ, Boyer-Pfersdorf P, Lebowitz MD,. Respiratory symptoms and risk factors in an Arizona population sample of Anglo and Mexican-American whites. Chest 1991; 99: 916-22.
4. Enright PL, Kronmal RA, Higgins MW, Schenker MB, Haponik EF,. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994; 106: 827-34.
5. Ford AC, Forman D, Moayyedi P, Morice AH,. Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. Thorax 2006; 61: 975-9.
6. Polley L, Yaman N, Heaney L, et al. Impact of cough across different chronic respiratory diseases: comparison of two cough-specific health-related quality of life questionnaires. Chest 2008; 134: 295-302.
7. Metlay JP, Stafford RS, Singer DE,. National trends in the use of antibiotics by primary care physicians for adult patients with cough. Arch Intern Med 1998; 158: 1813-8.
8. Jaspersen D, Kulig M, Labenz J, et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003; 17: 1515-20. (Pubitemid 36831442)
9. Poe RH, Kallay MC,. Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. Chest 2003; 123: 679-84.
10. Pratter MR, Bartter T, Akers S, DuBois J,. An algorithmic approach to chronic cough. Ann Intern Med 1993; 119: 977-83.
11. Smyrnios NA, Irwin RS, Curley FJ,. Chronic cough with a history of excessive sputum production. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Chest 1995; 108: 991-7.
12. Smyrnios NA, Irwin RS, Curley FJ, French CL,. From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults. Arch Intern Med 1998; 158: 1222-8.
13. Irwin RS, Curley FJ, French CL,. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis 1990; 141: 640-7.
14. Harding SM,. Gastroesophageal reflux and asthma: insight into the association. J Allergy Clin Immunol 1999; 1: 251-9.
15. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA,. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100: 395-405.
16. Harding SM, Sontag SJ,. Asthma and gastroesophageal reflux. Am J Gastroenterol 2000; 95 (Suppl.): S23-32.
17. Kiljander TO,. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am J Med 2003; 115 (Suppl. 3A): 65S-71S.
18. Kiljander TO, Salomaa ER, Hietanen EK, Terho EO,. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole. Chest 1999; 116: 1257-64.
19. Ours TM, Kavuru MS, Schilz RJ, Richter JE,. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999; 94: 3131-8.
20. Kiljander TO, Salomaa ER, Hietanen EK, Terho EO,. Chronic cough and gastro-oesophageal reflux: a double-blind placebo-controlled study with omeprazole. Eur Respir J 2000; 16: 633-8.
21. Irwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 144 (Suppl. Managing): 133S-81S.
22. Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. Eur Respir J 2004; 24: 481-92.
23. Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA,. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2006; 4: CD004823.
24. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA,. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ 2006; 332: 11-7.
25. Fisman EZ, Shapira I, Motro M, Pines A, Tenenbaum A,. The combined cough frequency/severity scoring: a new approach to cough evaluation in clinical settings. J Med 2001; 4: 181-7.
26. Rothman M, Farup C, Stewart W, Helbers L, Zeldis J,. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci 2001; 46: 1540-9.
27. Damiano A, Handley K, Adler E, Siddique R, Bhattacharyja A,. Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). Dig Dis Sci 2002; 47: 1530-7.
28. Damiano A, Siddique R, Xu X, Johanson J, Sloan S,. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig Dis Sci 2003; 48: 657-62.
29. Popa V,. ATS guidelines for methacholine and exercise challenge testing. Am J Respir Crit Care Med 2001; 163: 292-3.
30. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161: 309-29.
31. Fass R, Eidelman L, Garcia-Calderon W,. Ambulatory 24-hour esophageal pH monitoring. In:, Drossman DASN, Grimm IS, eds. Handbook of Gastroenterologic Procedures, 4th edn. Baltimore: Lippincott Williams & Wilkins, 2005; 299-305.
32. Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99: 1037-43.
33. Bredenoord AJ, Tutuian R, Smout AJ, Castell DO,. Technology review: esophageal impedance monitoring. Am J Gastroenterol 2007; 102: 187-94.
34. Tutuian R, Castell DO,. Multichannel intraluminal impedance: general principles and technical issues. Gastrointest Endosc Clin N Am 2005; 15: 257-64.
35. Johnson LF, DeMeester TR,. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986; 8 (Suppl. 1): 52-8.
36. Belafsky PC, Postma GN, Koufman JA,. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001; 111: 1313-7.
37. Belafsky PC, Rees CJ, Rodriguez K, Pryor JS, Katz PO,. Esophagopharyngeal reflux. Otolaryngol Head Neck Surg 2008; 138: 57-61.
38. Mastronarde JG, Anthonisen NR, Castro M, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med 2009; 360: 1487-99.
39. Reichel O, Dressel H, Wiederanders K, Issing WJ,. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg 2008; 139: 414-20.
40. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006; 116: 254-60.
41. Farrokhi F, Vaezi MF,. Extra-esophageal manifestations of gastroesophageal reflux. Oral Dis 2007; 13: 349-59.
42. Oridate N, Takeda H, Asaka M, et al. Acid-suppression therapy offers varied laryngopharyngeal and esophageal symptom relief in laryngopharyngeal reflux patients. Dig Dis Sci 2008; 53: 2033-8.
43. Charbel S, Khandwala F, Vaezi MF,. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100: 283-9.
44. French CT, Irwin RS, Fletcher KE, Adams TM,. Evaluation of a cough-specific quality-of-life questionnaire. Chest 2002; 121: 1123-31.
45. Field SK, Conley DP, Thawer AM, Leigh , Cowie RL,. Effect of the management of patients with chronic cough by pulmonologists and certified respiratory educators on quality of life: a randomized trial. Chest 2009; 136: 1021-8.